12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Methylene Blue MMX: Phase II data

An observational Phase II trial in 96 patients undergoing full colonoscopies showed that colonic staining with oral Methylene Blue MMX led to an average polyp detection rate in the whole colon of 1.8 polyps/patient and an adenoma detection rate of 0.9 adenomas/patient. Additionally, the company said polyps were detected in 63.5% of patients, adenomas in 46.9% of patients and serrated lesions...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >